DN 9693 | CAS# 96086-68-9 | inhibitor of platelet aggregation

MedKoo Cat#: 413870 | Name: DN 9693

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DN 9693 is a potent inhibitor of platelet aggregation.

Chemical Structure

DN 9693

CAS#96086-68-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 413870

Name: DN 9693

CAS#: 96086-68-9 (HCl)

Chemical Formula: C15H20Cl2N4O

Exact Mass: 342.1014

Molecular Weight: 343.25

Elemental Analysis: C, 52.49; H, 5.87; Cl, 20.66; N, 16.32; O, 4.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

96086-67-8 (free base) 96086-68-9 (HCl)

Synonym

DN 9693; DN9693; DN-9693

IUPAC/Chemical Name

Imidazo(2,1-b)quinazolin-2(3H)-one, 1,5-dihydro-7-(1-piperidinyl)-, dihydrochloride

InChi Key

CRIIVEDXIRIPQT-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H18N4O.2ClH/c20-14-10-19-9-11-8-12(18-6-2-1-3-7-18)4-5-13(11)16-15(19)17-14;;/h4-5,8H,1-3,6-7,9-10H2,(H,16,17,20);2*1H

SMILES Code

O=C1NC2=NC3=C(C=C(N4CCCCC4)C=C3)CN2C1.[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 343.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tanaka NG, Tohgo A, Ogawa H, Osada Y. Effects of DN-9693, a new metastasis inhibitor, on murine hematogenous metastasis. Anticancer Res. 1986 Jul- Aug;6(4):543-8. PMID: 3019218. 2: Kondo S, Tanaka N, Kubota S, Mukudai Y, Yosimichi G, Sugahara T, Takigawa M. Novel angiogenic inhibitor DN-9693 that inhibits post-transcriptional induction of connective tissue growth factor (CTGF/CCN2) by vascular endothelial growth factor in human endothelial cells. Mol Cancer Ther. 2006 Jan;5(1):129-37. doi: 10.1158/1535-7163.MCT-05-0097. PMID: 16432171. 3: Tanaka T, Kawai M, Kurihara S. Effects of a new inotropic drug (DN-9693) on Ca2+ transients and contraction in ferret ventricular muscles. J Cardiovasc Pharmacol. 1995 Aug;26(2):227-32. doi: 10.1097/00005344-199508000-00008. PMID: 7475047. 4: Iwatsuki K, Horiuchi A, Yonekura H, Haruta K, Homma N, Chiba S. Effects of DN-9693, a synthesized phosphodiesterase inhibitor, on pancreatic exocrine secretion in dogs. Jpn J Pharmacol. 1989 Jan;49(1):77-82. doi: 10.1254/jjp.49.77. PMID: 2470943. 5: Tanaka M, Yamada M, Ono K, Takegoshi T. Determination of 7-piperidino-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one (DN-9693) in human plasma and urine by high-performance liquid chromatography with electrochemical detection: application to studies on disposition of DN-9693 in healthy human volunteers. J Pharm Sci. 1987 Mar;76(3):235-7. doi: 10.1002/jps.2600760311. PMID: 3035171. 6: Akahane K, Furukawa Y, Haniuda M, Karasawa Y, Chiba S. Cardiovascular responses to a newly developed phosphodiesterase inhibitor, DN-9693 [7-pyperidinyl-1,2,3,5-tetrahydroimidazo (2,1-b)-quinazolin-2-one.HCl] in dog cross-circulated atrial and ventricular preparations. Jpn Heart J. 1989 Nov;30(6):903-15. doi: 10.1536/ihj.30.903. PMID: 2561162. 7: Tohgo A, Tanaka NG, Osada Y. Inhibitory effects of DN-9693 on platelet- enhanced tumor cell attachment to cultured endothelium. Invasion Metastasis. 1990;10(1):1-17. PMID: 2154413. 8: Jackson C, Ball J, Peel J, Lawry J, Greaves M, Preston FE. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect. Thromb Haemost. 1989 Apr 25;61(2):266-9. PMID: 2546286. 9: Hashimoto H, Ishii K, Satoh K, Taira N. Comparison of vasodilator effects of DN-9693, a selective inhibitor of cyclic AMP phosphodiesterase, and isobutylmethylxanthine, a non-selective one, in dogs. Jpn J Pharmacol. 1987 Aug;44(4):405-12. doi: 10.1254/jjp.44.405. PMID: 2446035. 10: Nakane T, Chiba S. Effects of DN-9693, a selective inhibitor of cyclic AMP phosphodiesterase, in isolated and perfused canine large coronary arteries. Jpn J Pharmacol. 1988 Dec;48(4):507-9. doi: 10.1254/jjp.48.507. PMID: 2468805.